Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Weight Loss in Non-Diabetic Obese/Overweight Subjects
NCT04487743Phase 3Unknown
- Sponsor
- Xiangya Hospital, Central South University
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Liraglutide with Placebo (2 arms). Primary endpoints: Mean Change From Baseline in Fasting Body Weight at Week 28 and Percentage of Subjects Losing at Least 5% of Baseline Fasting Body Weight at Week 28. Status: unknown.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04487743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04487743.